Pulse Biosciences (PLSE) Total Debt (2021 - 2023)

Pulse Biosciences (PLSE) posted quarterly Total Debt of $65.0 million for Q1 2023, little changed quarter-over-quarter from $65.0 million in Q4 2022.

Pulse Biosciences (PLSE) Total Debt (2021 - 2023) Analysis & Trends

Pulse Biosciences' Total Debt history runs 3 years deep, the most recent figure standing at $65.0 million for Q1 2023.

In Q1 2023, Total Debt changed N/A year-over-year to $65.0 million; the TTM figure through Mar 2023 stood at $65.0 million (changed N/A YoY), while the FY2022 annual figure was $65.0 million, changed N/A from the prior year.
Total Debt for Q1 2023 stood at $65.0 million, roughly flat from $65.0 million in the prior quarter.
The five-year high for Total Debt was $65.0 million in Q3 2022, with the low at $41.0 million in Q1 2021.
The 3-year median for Total Debt is $65.0 million (2022), against an average of $59.0 million.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Intuitive Surgical	132.71 Bn	127.50 Bn	1.96 Bn	-
2	Becton Dickinson	51.57 Bn	50.71 Bn	2.32 Bn	16.81 Bn
3	Alcon	35.52 Bn	34.17 Bn	1.68 Bn	4.72 Bn
4	Resmed	33.28 Bn	31.81 Bn	861.22 Mn	659.37 Mn
5	Medline	27.86 Bn	25.18 Bn	2.22 Bn	12.58 Bn
6	West Pharmaceutical Services	25.15 Bn	24.71 Bn	329.20 Mn	202.90 Mn
7	Solventum	15.31 Bn	14.91 Bn	1.29 Bn	5.08 Bn
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn	2.46 Bn
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn	9.46 Bn
10	Pulse Biosciences	3.33 Bn	3.33 Bn	161,000.00	-

Download Data